** Shares of biopharmaceutical firm Apellis Pharmaceuticals

fall 8.9% to $26.02

** APLS opens at near three-month low

** Co reports wider-than-expected loss in Q3

** Q3 loss at 46 cents/shr vs. estimates of loss of 30 cents/shr - LSEG

** Co reported Q3 rev of $196.8 mln vs. estimates of $200.35 mln - LSEG

** APLS's SYFOVRE injection, which treats a macular degeneration disorder called geographic atrophy (GA) received a negative opinion from the Committee for Medicinal Products for Human Use $(CHMP)$ in September

** SYFOVRE net selling price declined relative to previous quarters due to an increase in gross-to-net adjustments - APLS

** Co also expect regulatory decisions in the U.K., Switzerland, Canada and Australia in early 2025 for SYFORVE

** 15 of 21 analysts that cover APLS rate the stock "buy" or higher, 6 "hold", median PT is $68 - LSEG

** As of last close, stock down ~52% YTD

(Reporting by Ragini Mathur)

((Ragini.Mathur@thomsonreuters.com;))